Parkinson Disease, IdiopathicNCT05919160
A High-density Microelectrode for Human Neuronal Recordings
A study testing DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task in people with Parkinson Disease, Idiopathic, run by Cedars-Sinai Medical Center at 1 site in United States.
Trial summary
The purpose of this study is to test the ability of a newly-designed electrode to measure the activity of individual nerve cells (neurons), and collections of nerve cells (local field potentials) in the brain. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson Disease, Idiopathic
- What is being tested?
- DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Dec 2025to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Any patient undergoing implantation of a Deep Brain Stimulating (DBS) electrode in the Subthalamic nucleus (STN) for the treatment of Parkinson's disease, in whom microelectrode recording is being performed to improve localization of the STN.
- Age > 18 years of age
- Able to give independent informed consent
Who cannot join
- Microelectrode recording is not indicated
- Previous implantation of DBS electrodes in this site
- Known allergic reaction to stainless steel or polyimide
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Cedars-Sinai Medical Center
Los Angeles, California, 90048
About this study
Official title: Assessment of Safety and Utility of a High-density Microelectrode for Human Neuronal Recording
The purpose of this study is to test the ability of a newly-designed electrode to measure the activity of individual nerve cells (neurons), and collections of nerve cells (local field potentials) in the brain. The study's main goals are to see how well this electrode works compared to standard electrodes and to validate its safety.
Read the detailed description
Recording of human brain activity at many scales is an important tool in clinical medicine. The ability to record extracellular action potentials, otherwise known as a "single unit activity" (SUA) has provided fundamental insight into the details of neuronal function in humans as well as a variety of nonhuman animals. In humans the techniques for recording extracellular action potentials are relatively limited. Rigid, sharp tipped probes manufactured by several companies are FDA approved and routinely used as part of standard of care during a variety of surgical procedures such as deep brain stimulation (DBS) device implantation to identify areas of neuronal activity and optimize placement of clinical electrodes. The same technique has been used to better understand brain function and its impairment by disease in humans. In addition, a variety of semi- chronically implanted microwire techniques are available. These electrodes are more commonly used in patients with seizure disorders and have allowed insight into network behavior such as in the medial temporal lobe and medial frontal lobe.
However there remains a tremendous gap between the recording capabilities of modern electrodes used in animal research, and what is currently clinically available for human testing. A typical rigid shaft single electrode currently used in clinical care will record anywhere from 1-3 distinctly isolated neurons at a time. In contrast, in state-of-the art animal research, higher density probes such as the Neuropixel electrode [4-6] now routinely allow recording of hundreds or even thousands of neurons in a single brain region. This markedly increased recording capability translates directly into a better understanding of how brain neurons and networks interact to create complex behaviors and disease. Most of the commonly used high-density electrodes are based on a rigid silicon shaft onto which multiple recording contacts (typically made of platinum, Iridium, gold or conductive polymers) are embedded. There are several significant limitations of silicon-based probes in translating them to large brain, and in particular human, applications [7] First, silicon is fragile, making the electrodes prone to fracture, which makes them risky for human applications. Furthermore, the silicon microfabrication process is impractical for making large devices, limiting commercially available probe length to around 20mm, which is too short for most clinical applications in the human brain. Also, the connection between the electrode contacts and the pre-amplifier in the currently available products requires a rigid circuit board that is attached to the electrode, which is difficult to work with and which requires that the pre-amplifiers to be kept very close to the brain. While there are FDA approved version of silicon probes (i.e. the Utah Array used for brain machine interfaces), these applications are limited to short <2mm long probes used for surface cortical recordings. The inherent material and process limitations described make it unlikely that silicon-based probe technologies will provide a clinically usable probe for deeper locations in the human brain. The investigators, therefore, sought to utilize a new kind of translatable technology for clinical use.
The investigators seek to test a more robust and reliable technique for recording large numbers of single neurons in the human brain. Diagnostic Biochips Inc. (Glen Burnie, MD) is an electrode manufacturer that has developed a new type of electrode that consists of a stainless-steel shaft and an array of polyimide based high density electrodes that are embedded onto this shaft. This type of electrode design has proven highly reliable for deep brain penetrations of up to of up to 8cm length in rodent and non-human primate. The steel carrier is highly robust, entirely avoiding the breakage problems associated with silicon based and other high-density probe designs. Similarly, the polyimide-based electrodes are a material that is well known to not be biotoxic, which is well tolerated and part of numerous currently FDA approved products. The DBC Deep Array electrode is wired directly to an Intan (Los Angeles, CA) microprocessor mounted at the other end of the shaft. This microprocessor generates a digital signal, so that a long connection can be utilized between the microprocessor and Intan amplifier unit used to record the data, without any loss in signal or addition of noise. This feature is crucial to improve patient safety and reduce any infection risks during recording. Steel is rigid, and not prone to fracture like silicon. In addition, this type of electrode can be made significantly longer, simply by using a longer stainless-steel shaft to mount the high-density polyimide array on. While the currently manufactured DBC deep arrays used in animal research are 40-80 mm in length, a length of up to 300 mm is easily feasible. This contrasts with the maximal 10 -20 mm length that is achievable for silicon-based and other high-density systems. A length of >100mm is required for probing deep brain structures such as the basal ganglia in the human brain, which is routinely done in clinical settings. The DBC electrode can record up to 1024 individual channels simultaneously. The DBC devices have been used successfully in nonhuman primates and have undergone the biocompatibility, cytotoxicity, sterilization, and safety testing expected for use in humans. The results of these tests were all a pass, and the resulting reports are attached to this protocol.
- Conditions
- Parkinson Disease, Idiopathic
- Being tested
- DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task
- Keywords
- Parkinson's, DBS, Electrode
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral taskDevice
Devices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab)
| Study group | Role | What they receive |
|---|---|---|
| Neuronal Recording and Behavioral Testing | Experimental | Neuronal Recording and Behavioral Testing Receives: Device: DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neuronal Activity
Single Neuron firing rate (spikes) measured in spikes per second - total number of isolated neurons, amplitude (in uV of spikes) - by Intan Neurophysiology Recording System
Measured: One week after recording in OR completed
Breakage of Electrode
Extent of fracture of electrode tip measured in micrometers by a light microscope
Measured: One week after recording in OR completed
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2023
- Study start1 Dec 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson Disease, IdiopathicStudies of the same condition, open and under way.
- More trials run by Cedars-Sinai Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cedars-Sinai Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Adam Mamelak, MD, Cedars-Sinai Medical Center
- Investigators
- Adam Mamelak, MD, Principal investigator, Cedars-Sinai Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05919160
- Sponsor's protocol ID
- STUDY00002777
- Status last verified
- Dec 2025
- First submitted
- 9 Jun 2023
- Last updated
- 30 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Safety and Utility of a High-density Microelectrode for Human Neuronal Recording
- ClinicalTrials.gov ID
- NCT05919160
- Acronym / sponsor ID
- STUDY00002777
- Conditions
- Parkinson Disease, Idiopathic
- Keywords
- Parkinson's, DBS, Electrode
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Cedars-Sinai Medical CenterUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 26 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test the ability of a newly-designed electrode to measure the activity of individual nerve cells (neurons), and collections of nerve cells (local field potentials) in the brain. The study's main goals are to see how well this electrode works compared to standard electrodes and to validate its safety.
Detailed description
Recording of human brain activity at many scales is an important tool in clinical medicine. The ability to record extracellular action potentials, otherwise known as a "single unit activity" (SUA) has provided fundamental insight into the details of neuronal function in humans as well as a variety of nonhuman animals. In humans the techniques for recording extracellular action potentials are relatively limited. Rigid, sharp tipped probes manufactured by several companies are FDA approved and routinely used as part of standard of care during a variety of surgical procedures such as deep brain stimulation (DBS) device implantation to identify areas of neuronal activity and optimize placement of clinical electrodes. The same technique has been used to better understand brain function and its impairment by disease in humans. In addition, a variety of semi- chronically implanted microwire techniques are available. These electrodes are more commonly used in patients with seizure disorders and have allowed insight into network behavior such as in the medial temporal lobe and medial frontal lobe.
However there remains a tremendous gap between the recording capabilities of modern electrodes used in animal research, and what is currently clinically available for human testing. A typical rigid shaft single electrode currently used in clinical care will record anywhere from 1-3 distinctly isolated neurons at a time. In contrast, in state-of-the art animal research, higher density probes such as the Neuropixel electrode [4-6] now routinely allow recording of hundreds or even thousands of neurons in a single brain region. This markedly increased recording capability translates directly into a better understanding of how brain neurons and networks interact to create complex behaviors and disease. Most of the commonly used high-density electrodes are based on a rigid silicon shaft onto which multiple recording contacts (typically made of platinum, Iridium, gold or conductive polymers) are embedded. There are several significant limitations of silicon-based probes in translating them to large brain, and in particular human, applications [7] First, silicon is fragile, making the electrodes prone to fracture, which makes them risky for human applications. Furthermore, the silicon microfabrication process is impractical for making large devices, limiting commercially available probe length to around 20mm, which is too short for most clinical applications in the human brain. Also, the connection between the electrode contacts and the pre-amplifier in the currently available products requires a rigid circuit board that is attached to the electrode, which is difficult to work with and which requires that the pre-amplifiers to be kept very close to the brain. While there are FDA approved version of silicon probes (i.e. the Utah Array used for brain machine interfaces), these applications are limited to short <2mm long probes used for surface cortical recordings. The inherent material and process limitations described make it unlikely that silicon-based probe technologies will provide a clinically usable probe for deeper locations in the human brain. The investigators, therefore, sought to utilize a new kind of translatable technology for clinical use.
The investigators seek to test a more robust and reliable technique for recording large numbers of single neurons in the human brain. Diagnostic Biochips Inc. (Glen Burnie, MD) is an electrode manufacturer that has developed a new type of electrode that consists of a stainless-steel shaft and an array of polyimide based high density electrodes that are embedded onto this shaft. This type of electrode design has proven highly reliable for deep brain penetrations of up to of up to 8cm length in rodent and non-human primate. The steel carrier is highly robust, entirely avoiding the breakage problems associated with silicon based and other high-density probe designs. Similarly, the polyimide-based electrodes are a material that is well known to not be biotoxic, which is well tolerated and part of numerous currently FDA approved products. The DBC Deep Array electrode is wired directly to an Intan (Los Angeles, CA) microprocessor mounted at the other end of the shaft. This microprocessor generates a digital signal, so that a long connection can be utilized between the microprocessor and Intan amplifier unit used to record the data, without any loss in signal or addition of noise. This feature is crucial to improve patient safety and reduce any infection risks during recording. Steel is rigid, and not prone to fracture like silicon. In addition, this type of electrode can be made significantly longer, simply by using a longer stainless-steel shaft to mount the high-density polyimide array on. While the currently manufactured DBC deep arrays used in animal research are 40-80 mm in length, a length of up to 300 mm is easily feasible. This contrasts with the maximal 10 -20 mm length that is achievable for silicon-based and other high-density systems. A length of >100mm is required for probing deep brain structures such as the basal ganglia in the human brain, which is routinely done in clinical settings. The DBC electrode can record up to 1024 individual channels simultaneously. The DBC devices have been used successfully in nonhuman primates and have undergone the biocompatibility, cytotoxicity, sterilization, and safety testing expected for use in humans. The results of these tests were all a pass, and the resulting reports are attached to this protocol.
Study design
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Neuronal Recording and Behavioral Testing | Experimental | Device: DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral taskNeuronal Recording and Behavioral Testing |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Any patient undergoing implantation of a Deep Brain Stimulating (DBS) electrode in the Subthalamic nucleus (STN) for the treatment of Parkinson's disease, in whom microelectrode recording is being performed to improve localization of the STN.
- Age > 18 years of age
- Able to give independent informed consent
Key exclusion criteria (3 listed)
- Microelectrode recording is not indicated
- Previous implantation of DBS electrodes in this site
- Known allergic reaction to stainless steel or polyimide
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral taskDevices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab) | Device | Neuronal Recording and Behavioral Testing |
Primary outcome
Neuronal Activity
Time frame: One week after recording in OR completed
Single Neuron firing rate (spikes) measured in spikes per second - total number of isolated neurons, amplitude (in uV of spikes) - by Intan Neurophysiology Recording System
Breakage of Electrode
Time frame: One week after recording in OR completed
Extent of fracture of electrode tip measured in micrometers by a light microscope
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease, Idiopathic
Not yet recruitingObservational study
Longitudinal Observation of Neurodegeneration in Parkinson's Disease Using Molecular Imaging and Blood Biomarkers
Idiopathic Parkinson Disease
Not yet recruiting
Non-invasive Vagus Nerve Stimulation for Parkinson's Disease
Idiopathic Parkinson Disease
RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson Disease, Parkinson
Recruiting
MediPD: An Online Mediterranean Diet Program for People Living With Parkinson's Disease
Parkinson Disease, Idiopathic
Recruiting
Ginger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease
REM Sleep Behavior Disorder, Parkinson s Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Adam Mamelak, MD principal investigator
Cedars-Sinai Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task in people with Parkinson Disease, Idiopathic, run by Cedars-Sinai Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 30 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neuronal Activity (time frame: One week after recording in OR completed). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2025.